NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

Search

Lonza Group AG

Avatud

SektorTervishoid

530.6 -2.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

525

Max

545

Põhinäitajad

By Trading Economics

Sissetulek

329M

Müük

3.1B

P/E

Sektori keskmine

60.853

63.778

Aktsiakasum

4.31

Dividenditootlus

0.71

Kasumimarginaal

10.762

Töötajad

18,686

EBITDA

824M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+23.77% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.71%

2.39%

Turustatistika

By TradingEconomics

Turukapital

-3B

39B

Eelmine avamishind

532.85

Eelmine sulgemishind

530.6

Uudiste sentiment

By Acuity

20%

80%

40 / 386 Pingereas Healthcare

Lonza Group AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2025, 12:22 UTC

Omandamised, ülevõtmised, äriostud

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12. dets 2024, 09:26 UTC

Omandamised, ülevõtmised, äriostud

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12. dets 2024, 07:45 UTC

Omandamised, ülevõtmised, äriostud

Lonza Streamlines Business With Capsules Unit Exit -- Update

12. dets 2024, 06:52 UTC

Omandamised, ülevõtmised, äriostud

Lonza Streamlines Organizational Structure

24. okt 2024, 05:40 UTC

Tulu

Lonza Expects Accelerating Sales Growth in Final Quarter

29. jaan 2025, 08:11 UTC

Market Talk
Tulu

Lonza's Outlook Looks Positive -- Market Talk

29. jaan 2025, 07:22 UTC

Market Talk
Tulu

Lonza Had a Mixed Year Across Divisions -- Market Talk

29. jaan 2025, 07:11 UTC

Market Talk
Tulu

Lonza's Results Don't Contain Any Surprises -- Market Talk

29. jaan 2025, 06:26 UTC

Peamised uudised
Tulu

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16. jaan 2025, 10:32 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Lonza's Midterm Outlook Is Positive -- Market Talk

16. dets 2024, 22:03 UTC

Peamised uudised

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13. dets 2024, 08:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12. dets 2024, 08:51 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12. dets 2024, 08:02 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12. dets 2024, 05:59 UTC

Omandamised, ülevõtmised, äriostud

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12. dets 2024, 05:59 UTC

Omandamised, ülevõtmised, äriostud

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12. dets 2024, 05:58 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12. dets 2024, 05:58 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12. dets 2024, 05:58 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12. dets 2024, 05:57 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12. dets 2024, 05:55 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12. dets 2024, 05:54 UTC

Omandamised, ülevõtmised, äriostud

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12. dets 2024, 05:54 UTC

Omandamised, ülevõtmised, äriostud

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12. dets 2024, 05:53 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12. dets 2024, 05:53 UTC

Omandamised, ülevõtmised, äriostud

Lonza Sees Flat 2024 CER Sales Growth

12. dets 2024, 05:52 UTC

Omandamised, ülevõtmised, äriostud

Lonza Backs 2024 View

12. dets 2024, 05:52 UTC

Omandamised, ülevõtmised, äriostud

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

12. dets 2024, 05:52 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Exit Capsules, Health Ingredients Business at Appropriate Time

12. dets 2024, 05:51 UTC

Omandamised, ülevõtmised, äriostud

Lonza Outlines Strategy, New Organizational Structure and Guidance

24. okt 2024, 06:37 UTC

Market Talk
Tulu

Lonza 3Q Update Didn't Surprise -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lonza Group AG Prognoos

Hinnasiht

By TipRanks

23.77% tõus

12 kuu keskmine prognoos

Keskmine 671.07 CHF  23.77%

Kõrge 744 CHF

Madal 625 CHF

Põhineb 11 Wall Streeti analüütiku instrumendi Lonza Group AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

9

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

40 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.